Lakefront Biotherapeutics - Sponsored ADR LKFT

29.38 (0.98) (3.23%) as of 25 Sep
Market cap
$2.0B
P/E
0.0×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
167.77 176.23 375.37 1,003.40 605.72 573.62 532.36 259.45 298.28 1,258.40
Revenue Growth
149.42% 5.04% 113.00% 167.31% (39.63%) (5.30%) (7.19%) (51.26%) 14.96% 321.88%
Gross Profit
167.77 176.23 375.37 1,003.40 605.72 571.69 519.64 259.45 260.55 1,224.75
Operating Income
(12.71) (101.50) (52.92) 414.73 (204.05) (195.92) (281.86) (95.53) (203.80) 333.81
EBT
60.03 (130.56) (34.50) 168.07 (353.86) (145.52) (226.68) 6.09 (3.34) 340.41
Income after Tax
59.77 (130.78) (34.55) 167.83 (355.26) (148.39) (229.68) (4.32) (1.39) 361.47
Net Income Common
59.77 (130.78) (34.55) 167.83 (348.90) (122.13) (229.68) 229.12 80.16 363.05
EPS (Diluted)
1.24 (2.64) (0.66) 2.79 (5.46) (1.87) (3.50) 3.47 1.21 5.51
Shares (Diluted, Weighted)
47.31 49.48 52.11 60.11 65.08 65.50 65.70 65.93 65.94 65.90
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 99.66% 97.61% 100.00% 87.35% 97.33%
EBIT Margin
(7.58%) (57.60%) (14.10%) 41.33% (33.69%) (34.15%) (52.94%) (36.82%) (68.33%) 26.53%
Net Profit Margin
35.63% (74.21%) (9.21%) 16.73% (57.60%) (21.29%) (43.14%) 88.31% 26.88% 28.85%
Free Cash Flow Margin
154.76% (99.06%) (49.14%) 353.05% (97.80%) (115.85%) (106.23%) (176.38%) (145.89%) (24.35%)
EBITDA
(8.09) (96.66) (46.92) 428.67 (182.71) (154.94) (212.78) (48.29) (154.57) 397.02
EBIT
(12.71) (101.50) (52.92) 414.73 (204.05) (195.92) (281.86) (95.53) (203.80) 333.81

Show all line items

In millions of $ except per-share values · columns are period end dates